Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi
K
K
Mayo Clinic, Rochester, Minnesota, USA.
Munn
S R
SR
Sterioff
S
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D007683:Kidney Tubular Necrosis, Acute / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine; D011239:Prednisolone; D003404:Creatinine; D001379:Azathioprine